Will Vivani’s Tiny GLP-1 Implant Disrupt the $100B Weight Loss Market?
Obesity treatment has shifted from a niche pharmaceutical market to one of the most lucrative sectors in global healthcare. While GLP-1 agonists like Wegovy and Ozempic have generated billions in revenue for Novo Nordisk (NVO), long-term patient adherence remains a major commercial hurdle. High out-of-pocket costs, side effects, and injection fatigue cause over 50% of … Read more

